Large scale expansion of γ9δ2 T lymphocytes: Innacell γδ™ cell therapy product

Journal of Immunological Methods

Volumn 326, Issue 1-2, 2007, Pages 63-75

  Salot, Samuel ^a   Laplace, Catherine ^a   Saïagh, Soraya ^b   Bercegeay, Sylvain ^b   Tenaud, Isabelle ^b   Cassidanius, Alain ^b   Romagne, François ^a   Dreno, Brigitte ^b   Tiollier, Jérôme ^a  

^a INNATE PHARMA   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

9 2 T lymphocytes; BrHPP; Cell therapy product; Phosphoantigen

Indexed keywords

BROMOHYDRIN PYROPHOSPHATE; CELL THERAPY AGENT; CYTOKINE; HUMAN SERUM ALBUMIN; INNACELL; INTERLEUKIN 2; PYROPHOSPHORIC ACID DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL POPULATION; CELL THERAPY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR; TUMOR CELL;

CARCINOMA, RENAL CELL; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKAPHERESIS; LYMPHOCYTE COUNT; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 34548393650     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2007.07.010     Document Type: Article

References (51)

1. Baccala R., Witherden D., Gonzalez-Quintial R., Dummer W., Surh C.D., Havran W.L., and Theofilopoulos A.N. Gamma delta T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. J. Immunol. 174 (2005) 4606
2. Bank I., Book M., Huszar M., Baram Y., Schnirer I., and Brenner H. V delta 2+gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors. Clin. Immunol. Immunopathol. 67 (1993) 17
3. Belmant C., Espinosa E., Halary F., Tang Y., Peyrat M.A., Sicard H., Kozikowski A., Buelow R., Poupot R., Bonneville M., and Fournie J.J. A chemical basis for selective recognition of nonpeptide antigens by human γδ T cells. FASEB J. 14 (2000) 1669
4. Bendelac A., Bonneville M., and Kearney J.F. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1 (2001) 177
5. Bompas E., Neidhardt E.M., Rolland F., Philip I., Galéa C., Salot S., Tiollier J., Saiagh S., Negrier S., and Bennouna J. An autologous Vγ9Vδ2 T lymphocytes cell therapy product generated by BrHPP (INNACELL Gamma Delta [GD]) in metastatic renal cell carcinoma patients: phase I clinical trial results. J. Clin. Oncol. 24 (2006) 2550 Meeting Abstracts
6. Bonneville M., and Fournie J.J. Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 7 (2005) 503
7. Brenner M.B., McLean J., Scheft H., Riberdy J., Ang S.L., Seidman J.G., Devlin P., and Krangel M.S. Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. Nature 325 (1987) 689
8. Bukowski J.F., Morita C.T., Tanaka Y., Bloom B.R., Brenner M.B., and Band H. V gamma 2 V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 154 (1995) 998
9. Choudhary A., Davodeau F., Moreau A., Peyrat M.A., Bonneville M., and Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 154 (1995) 3932
10. Constant P., Davodeau F., Peyrat M.A., Poquet Y., Puzo G., Bonneville M., and Fournie J.J. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264 (1994) 267
11. Corvaisier M., Moreau-Aubry A., Diez E., Bennouna J., Mosnier J.F., Scotet E., Bonneville M., and Jotereau F. V gamma 9V delta 2 T cell response to colon carcinoma cells. J. Immunol. 175 (2005) 5481
12. Davodeau F., Peyrat M.A., Hallet M.M., Gaschet J., Houde I., Vivien R., Vie H., and Bonneville M. Close correlation between Daudi and mycobacterial antigen recognition by human gamma delta T cells and expression of V9JPC1 gamma/V2DJC delta-encoded T cell receptors. J. Immunol. 151 (1993) 1214
13. Dieli F., Poccia F., Lipp M., Sireci G., Caccamo N., Di Sano C., and Salerno A. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 198 (2003) 391
14. Espinosa E., Belmant C., Pont F., Luciani B., Poupot R., Romagne F., Brailly H., Bonneville M., and Fournie J.J. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J. Biol. Chem. 276 (2001) 18337
15. Espinosa E., Belmant C., Sicard H., Poupot R., Bonneville M., and Fournié J.J. Y2K_1 state-of-the-art on non-peptide phosphoantigens, a novel category of immunostimulatory molecules. Microbes Infect. 3 (2001) 645
16. Fearon D.T., and Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 272 (1996) 50
17. Ferrarini M., Heltai S., Pupa S.M., Mernard S., and Zocchi R. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) T-cell receptors. J. Natl. Cancer Inst. 88 (1996) 436
18. Fisch P., Meuer E., Pende D., Rothenfusser S., Viale O., Kock S., Ferrone S., Fradelizi D., Klein G., Moretta L., Rammensee H.G., Boon T., Coulie P., and van der Bruggen P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur. J. Immunol. 27 (1997) 3368
19. Fujimiya Y., Suzuki Y., Katakura R., Miyagi T., Yamaguchi T., Yoshimoto T., and Ebina T. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. Clin. Cancer Res. 3 (1997) 633
20. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197 (2003) 163
21. Guo B.L., Liu Z., Aldrich W.A., and Lopez R.D. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells. Breast Cancer Res. Treat. 93 (2005) 169
22. Hayday A.C. γδ cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18 (2000) 975
23. Hintz M., Reichenberg A., Altincicek B., Bahr U., Gschwind R.M., Kollas A.K., Beck E., Wiesner J., Eberl M., and Jomaa H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human T cells in Escherichia coli. FEBS Lett. 509 (2001) 317
24. Ibisch C., Saulquin X., Gallot G., Vivien R., Ferrand C., Tiberghien P., Houssaint E., and Vie H. The T cell repertoire selected in vitro against EBV: diversity, specificity, and improved purification through early IL-2 receptor alpha-chain (CD25)-positive selection. J. Immunol. 164 (2000) 4924
25. Jomaa H., Feurle J., Luhs K., Kunzmann V., Tony H.P., Herderich M., and Wilhelm M. Vγ9Vδ2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-d-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol. Med. Microbiol. 25 (1999) 371
26. Kobayashi H., Tanaka Y., Yagi J., Toma H., and Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. 50 (2001) 115
27. Kroca M., Johansson A., Sjostedt A., and Tarnvik A. V gamma 9V delta 2 T cells in human legionellosis. Clin. Diagn. Lab. Immunol. 8 (2001) 949
28. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75
29. Lin J.H., Russell G., and Gertz B. Pharmacokinetics of alendronate: an overview. Int. J. Clin. Pract., Suppl. 101 (1999) 18
30. Liu Z., Guo B.L., Gehrs B.C., Nan L., and Lopez R.D. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J. Urol. 173 (2005) 1552
31. Lopez R.D., Xu S., Guo B., Negrin R.S., and Waller E.K. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96 (2000) 3827
32. Mak T.W., and Ferrick D.A. The gammadelta T-cell bridge: linking innate and acquired immunity. Nat. Med. 4 (1998) 764
33. Miller J.S., Klingsporn S., Lund J., Perry E.H., Verfaillie C., and McGlave P. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant. 14 (1994) 555
34. Mitropoulos D., Kooi S., Rodriguez-Villanueva J., and Platsoucas C.D. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 97 (1994) 321
35. Otto M., Barfield R.C., Martin W.J., Iyengar R., Leung W., Leimig T., Chaleff S., Gillies S.D., and Handgretinger R. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin. Cancer Res. 11 (2005) 8486
36. Parker C.M., Groh V., Band H., Porcelli S.A., Morita C., Fabbi M., Glass D., Strominger J.L., and Brenner M.B. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J. Exp. Med. 171 (1990) 1597
37. Poupot M., and Fournie J.J. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes. Immunol. Lett. 95 (2004) 129
38. Schultze J.L., and Nadler L.M. T cell mediated immunotherapy for B cell lymphoma. J. Mol. Med. 77 (1999) 322-331
39. Scotet E., Martinez L.O., Grant E., Barbaras R., Jeno P., Guiraud M., Monsarrat B., Saulquin X., Maillet S., and Estève J.P. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22 (2005) 71
40. Sicard H., Al Saati T., Delsol G., and Fournie J.J. Synthetic phosphoantigens enhance human Vg9Vd2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol. Med. 7 (2001) 711
41. Sicard H., Ingoure S., Luciani B., Serraz C., Fournie J.J., Bonneville M., Tiollier J., and Romagne F. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175 (2005) 5471
42. Sturm E., Braakman E., Fisch P., Vreugdenhil R.J., Sondel P., and Bolhuis R.L. Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J. Immunol. 145 (1990) 3202
43. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375 (1995) 155
44. Vely F., Peyrat M., Couedel C., Morcet J., Halary F., Davodeau F., Romagne F., Scotet E., Saulquin X., Houssaint E., Schleinitz N., Moretta A., Vivier E., and Bonneville M. Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J. Immunol. 166 (2001) 2487
45. Viey E., Fromont G., Escudier B., Morel Y., Da Rocha S., Chouaib S., and Caignard A. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174 (2005) 1338
46. Viey E., Laplace C., and Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 5 (2005) 973
47. Walzer T., Dalod M., Vivier E., and Zitvogel L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin. Biol. Ther. Suppl. 1 (2005) S49
48. Wesch D., Marx S., and Kabelitz D. Comparative analysis of alpha beta and gamma delta T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate. Eur. J. Immunol. 27 (1997) 952
49. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger T., and Tony H.P. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102 (2003) 200
50. Yamaguchi T., Fujimiya Y., Suzuki Y., Katakura R., and Ebina T. A simple method for the propagation and purification of gamma delta T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J. Immunol. Methods 205 (1997) 19
51. Zheng B.J., Chan K.W., Im S., Chua D., Sham J.S., Tin P.C., He Z.M., and Ng M.H. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int. J. Cancer 92 (2001) 421